Accessibility Menu
Vistagen Therapeutics logo

Vistagen Therapeutics

(NASDAQ) VTGN

Current Price$0.23
Market Cap$9.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2011)-100%
5 Year-100%
1 Year-90%
1 Month-65%
Vistagen Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.242026-07-16
Vistagen Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.69%USD 0.252026-07-09
1 month-65.22%USD 0.692026-06-16
3 month-61.77%USD 0.632026-04-17
Year to date-63.74%USD 0.662025-12-31
1 year-90.28%USD 2.472025-07-16
3 year-86.74%USD 1.812023-07-17
5 year-99.71%USD 82.202021-07-16
Since inception-99.98%USD 1,470.002011-06-21

Vistagen Therapeutics Financials at a Glance

Market Cap

$9.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.27M

Net Income (TTM)

-$69.69M

EPS (TTM)

-$1.87

P/E Ratio

-0.13

Dividend

$0.00

Beta (Volatility)

2.09 (High)

Price

$0.23

Volume

523,162.824

Open

$0.24

Previous Close

$0.24

Daily Range

$0.23 - $0.24

52-Week Range

$0.20 - $5.14

Estimated Earnings Date

Aug 6, 2026

VTGN News

Foolcom-Featured.png

Vistagen (VTGN) Q1 R&D Expense Jumps 54%

Motley Fool Markets TeamAug 7, 2025
Scientist looking through a microscope

Why VistaGen Therapeutics Stock Jumped Today

Keith SpeightsJun 30, 2021
Thumb up and money

Why VistaGen Therapeutics Stock Is Soaring Today

Keith SpeightsFeb 18, 2021

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Vistagen Therapeutics

VistaGen develops nasal sprays for anxiety and depression. Its medicines aim to help adults manage social anxiety and mood disorders. These products target people seeking fast relief from mental health symptoms.

What’s in the Medicine Cabinet?

  • Fasedienol (PH94B): Nasal spray for social anxiety disorder; in late-stage clinical trials.
  • Itruvone (PH10): Nasal spray for major depressive disorder; preparing for mid-stage clinical trials.
  • PH80: Nasal spray for menopause-related hot flashes and premenstrual mood symptoms; completed early clinical studies.
  • PH15: Nasal spray for mental fatigue; completed pilot clinical study.
  • PH284: Nasal spray for weight loss in cancer patients; completed early clinical study.
  • AV-101: Oral medicine for movement disorders and depression; in early development.

Growth Spurts and New Friends

  • Signed licensing deal with AffaMed Therapeutics in 2020 for Asian markets.
  • Entered exclusive talks with Fuji Pharma in 2023 for Japanese rights to PH80.
  • Received $1.5 million upfront from Fuji Pharma in 2023.
  • Expanded product pipeline with new nasal spray candidates between 2022 and 2025.
  • Launched at-the-market equity program with Jefferies LLC in 2021.

Why VistaGen Stands Out (Without the Hype)

VistaGen focuses on fast-acting nasal sprays that work through the nose, not the bloodstream. Its approach targets brain pathways linked to anxiety and depression. The company partners with regional firms to reach global markets.

Five Things You Need to Know

  • Revenue was $258,000 in QQ2 2026, up 41% from QQ2 2025.
  • Net loss was $20 million in QQ2 2026, 41% higher than QQ2 2025.
  • Cash and securities totaled $63.2 million as of June 30, 2025.
  • All revenue comes from licensing, not product sales, as of QQ2 2026.
  • Operating cash burn was $18.8 million for the quarter ended June 30, 2025.

Bottom Line

VistaGen is evolving as a developer of nasal sprays for mental health. Its business relies on partnerships and licensing while advancing clinical trials.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

41

CEO

Shawn K. Singh

Website

www.vistagen.com

Headquarters

South San Francisco, CA 94080, US

VTGN Financials

Key Financial Metrics (TTM)

Gross Margin

71.81%

Operating Margin

-5678.74%

Net Income Margin

-5487.01%

Return on Equity

-133.02%

Return on Capital

-197.26%

Return on Assets

-143.49%

Earnings Yield

-7.69%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$9.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

41.03M

Volume

523.16K

Avg. Volume

2.13M

Financials (TTM)

Gross Profit

$912.00K

Operating Income

-$72.12M

EBITDA

-$69.40M

Operating Cash Flow

-$66.44M

Capital Expenditure

-$190.00K

Free Cash Flow

-$66.50M

Cash & ST Invst.

$45.40M

Total Debt

$1.04M

Vistagen Therapeutics Performance Analysis

Vistagen Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31USD -227,300N/A
20242024-03-31USD 1,064,000N/A
20252025-03-31USD 486,000-54.3%
20262026-03-31USD 1,269,000161.1%
Vistagen Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-301726.7%
Q22025-09-305.7%
Q32025-12-3117.4%
Q42026-03-3153.5%
Vistagen Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31USD -8.5115.4%
20242024-03-31USD -1.52-82.2%
20252025-03-31USD -1.679.8%
20262026-03-31USD -1.839.9%
Vistagen Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-30-6.8%
Q22025-09-30-14.9%
Q32025-12-3116.7%
Q42026-03-318.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

$465.00K

+3200.0%

Gross Profit

$465.00K

+3200.0%

Gross Margin

100.00%

N/A

Market Cap

$9.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$240.19K

N/A

Employees

41

N/A

Net Income

-$16.27M

-19.4%

EBITDA

-$16.53M

-22.7%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

$45.40M

-43.6%

Total Debt

$1.04M

-30.8%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$249.00K

-73.7%

Short Term Debt

$795.00K

+41.7%

Return on Assets

-1.43%

N/A

Return on Invested Capital

-2.02%

N/A

Free Cash Flow

-$16.20M

-59.6%

Operating Cash Flow

-$16.20M

-61.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ACTUActuate Therapeutics Inc
$1.52-8.73%
MCRBSeres Therapeutics, Inc.
$5.30+2.32%
INOInovio Pharmaceuticals, Inc.
$1.12-0.58%
CGTXCognition Therapeutics, Inc.
$0.98+3.95%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$15.12-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$69.42-0.02%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$30.23+0.10%
PATHUiPath
$12.30+0.02%

Questions About VTGN

What is the current price of Vistagen Therapeutics?

Vistagen Therapeutics is trading at $0.23 per share.

What is the 52-week range for Vistagen Therapeutics?

Over the past 52 weeks, Vistagen Therapeutics has traded between $0.20 and $5.14.

How much debt does Vistagen Therapeutics have?

As of the most recent reporting period, Vistagen Therapeutics reported total debt of $1.04M.

How much cash does Vistagen Therapeutics have on hand?

Vistagen Therapeutics reported $30.79M in cash and cash equivalents in its most recent financial results.

What is Vistagen Therapeutics’s dividend yield?

Vistagen Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services